Lung cancer in never smokers: Distinct population-based patterns by age, sex, and race/ethnicity. Pinheiro PS et al.Lung…
この記事を読む
記事一覧 8ページ
この記事を読む
ALTA-2:アレクチニブ後のブリグチニブ
Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lun…
この記事を読む
ICI化学療法終了後のラムシルマブ＋アテゾリズマブ
Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkp…
この記事を読む
肺癌患者へのブースター接種後のオミクロン株に対する抗体の推移
Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivi…
この記事を読む
肺癌治療の進歩にもかかわらず、まだ気管支漏には対処が難しい
Bronchorrhea, a Rare and Debilitating Symptom of Lung Cancer: Case Report and Review of the Treatment. Bhagat M et al.JT…
この記事を読む
PETによる原発巣と転移巣の効果判定の不一致
18F-FDG PET/CT for assessing heterogeneous metabolic response between primary tumor and metastases and prognosis in non-…
この記事を読む
ペムブロリズマブ3週から6週間隔への変更でirAEが増える可能性
Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With…
この記事を読む
ICIの長期成績、日本人の実地データで4生率17.9%
Long-Term Survival of Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor Monotherapy in R…
この記事を読む
小細胞肺癌に対する免疫療法の実地データ
Real-world evidence for immunotherapy in the first line setting in small cell lung cancer Shira Sagie et al.lung Cancer …
この記事を読む
ヒスパニック系におけるオシメルチニブの耐性機序
Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRE…